NCT07635563
DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.
Recruiting
PHASE2Ages 18–65InterventionalTreatmentIncannex Healthcare Ltd
~120 participants
Updated 2026-07-27 on ClinicalTrials.gov
What's tested:IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamideIHL-42X: 5 mg dronabinol + 125 mg acetazolamideIHL-42X: 7.5 mg dronabinol + 125 mg acetazolamideIHL-42X: 2.5 mg dronabinol + 250 mg acetazolamideIHL-42X: 5 mg dronabinol + 250 mg acetazolamideIHL-42X: 7.5 mg dronabinol + 250 mg acetazolamide
At a glance
Recruiting sites
2 of 14 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in AHI4 at the end of each treatment period compared to baseline
Measured over Each treatment period (28 days)
Conditions
Where it's being run
14 sites across 8 statesFlorida5
Ohio2
Texas2
California1
Louisiana1
Maryland1
South Carolina1
Tennessee1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change in AHI4 at the end of each treatment period compared to baselineEach treatment period (28 days)
To assess the change in efficacy at the end of each dosing period compared with baseline.